• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

K-ras基因第13密码子的特定突变可预测结直肠癌患者的临床结局,而K-ras基因第12密码子的突变与黏液组织学类型相关。

Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype.

作者信息

Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri M A, La Farina M, Albanese I, Dardanoni G, Salerno S, Tomasino R M, Labianca R, Gebbia N, Russo A

机构信息

Department of Oncology, Section of Molecular Oncology, University of Palermo, Palermo Italy.

出版信息

Ann Oncol. 2002 Sep;13(9):1438-46. doi: 10.1093/annonc/mdf226.

DOI:10.1093/annonc/mdf226
PMID:12196370
Abstract

BACKGROUND

K-ras mutations, one of the earliest events observed in colorectal carcinogenesis, are mostly found in codons 12 and 13, and less frequently in codon 61, all three of which are estimated to be critical for the biological activity of the protein. Nevertheless the prognostic significance of such mutations remains controversial. Our purpose was to assess whether any or specific K-ras mutations in primary colorectal cancer had prognostic significance and were linked to clinico-pathological parameters.

PATIENTS AND METHODS

Paired tumor and normal tissue samples from a consecutive series of 160 untreated patients (median of follow up 71 months), undergoing resective surgery for primary colorectal carcinoma, were prospectively studied for K-ras mutations by PCR/single strand conformation polymorphism sequencing.

RESULTS

Seventy-four of the 160 (46%) primary colorectal carcinomas presented mutations in K-ras: 54% in codon 12, 42% in codon 13 (particularly G-->A transition) and 4% in both. Codon 12 K-ras mutations were associated with mucinous histotype (P <0.01), while codon 13 K-ras mutations were associated with advanced Dukes' stage (P <0.05), lymph-node metastasis (P <0.05) and high S-phase fraction (P <0.05). Multivariate analysis showed that codon 13 K-ras mutations, but not any mutation, were independently related to risk of relapse or death.

CONCLUSIONS

Our results suggest that codon 12 K-ras mutations may have a role in the mucinous differentiation pathway, while codon 13 mutations have biological relevance in terms of colorectal cancer clinical outcome.

摘要

背景

K-ras突变是在结直肠癌发生过程中最早观察到的事件之一,大多发生在密码子12和13,较少发生在密码子61,据估计这三个密码子对该蛋白的生物学活性都至关重要。然而,此类突变的预后意义仍存在争议。我们的目的是评估原发性结直肠癌中任何或特定的K-ras突变是否具有预后意义,并与临床病理参数相关。

患者与方法

对连续160例未经治疗的患者(中位随访71个月)进行前瞻性研究,这些患者因原发性结直肠癌接受切除手术,通过聚合酶链反应/单链构象多态性测序对配对的肿瘤和正常组织样本进行K-ras突变检测。

结果

160例原发性结直肠癌中有74例(46%)出现K-ras突变:密码子12突变占54%,密码子13突变占42%(特别是G→A转换),两者同时突变占4%。密码子12的K-ras突变与黏液组织学类型相关(P<0.01),而密码子13的K-ras突变与Dukes分期晚期(P<0.05)、淋巴结转移(P<0.05)和高S期分数(P<0.05)相关。多变量分析显示,密码子13的K-ras突变而非任何突变与复发或死亡风险独立相关。

结论

我们的结果表明,密码子12的K-ras突变可能在黏液分化途径中起作用,而密码子13的突变在结直肠癌临床结局方面具有生物学相关性。

相似文献

1
Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype.K-ras基因第13密码子的特定突变可预测结直肠癌患者的临床结局,而K-ras基因第12密码子的突变与黏液组织学类型相关。
Ann Oncol. 2002 Sep;13(9):1438-46. doi: 10.1093/annonc/mdf226.
2
Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: a report.克什米尔地区结直肠癌患者K-ras基因的突变模式:一份报告。
Indian J Cancer. 2009 Jul-Sep;46(3):219-25. doi: 10.4103/0019-509X.52956.
3
APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.结直肠癌患者中APC、K-ras和p53基因突变:与临床病理特征及术后监测的相关性
Am Surg. 2005 Apr;71(4):336-43.
4
Molecular staging of colorectal cancer: K-ras mutation analysis of lymph nodes upstages Dukes B patients.结直肠癌的分子分期:对淋巴结进行K-ras突变分析可使Dukes B期患者分期上调。
Dis Colon Rectum. 2000 Feb;43(2):155-9; discussion 159-62. doi: 10.1007/BF02236973.
5
K-ras codon 12 and 13 mutations are correlated with differential patterns of tumor cell dissemination in colorectal cancer patients.K-ras基因第12和13密码子突变与结直肠癌患者肿瘤细胞播散的不同模式相关。
Int J Oncol. 2004 Jun;24(6):1537-44.
6
DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma: results of a 5-year Gruppo Oncologico dell'Italia Meridonale (GDIM) prospective study.DNA非整倍体和高增殖活性而非K-ras-2突变作为可手术胃癌临床结局的独立预测因素:意大利南部肿瘤学研究组(GDIM)5年前瞻性研究结果
Cancer. 2001 Jul 15;92(2):294-302. doi: 10.1002/1097-0142(20010715)92:2<294::aid-cncr1322>3.0.co;2-9.
7
Detection of isolated tumor cells by polymerase chain reaction-restriction fragment length polymorphism for K-ras mutations in tissue samples of 199 colorectal cancer patients.采用聚合酶链反应-限制性片段长度多态性方法检测199例结直肠癌患者组织样本中K-ras突变的孤立肿瘤细胞。
Clin Cancer Res. 2004 Jan 15;10(2):641-50. doi: 10.1158/1078-0432.ccr-1355-02.
8
K-ras gene point mutations and p21ras immunostaining in human ovarian tumors.人类卵巢肿瘤中的K-ras基因点突变与p21ras免疫染色
Eur J Gynaecol Oncol. 2004;25(4):484-8.
9
p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer.p53和K-ras基因突变与肿瘤侵袭性相关,但在结直肠癌中并无常规预后价值。
J Clin Oncol. 1999 May;17(5):1375-81. doi: 10.1200/JCO.1999.17.5.1375.
10
Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality.原发性和转移性结直肠癌中突变型与野生型Ki-ras的异质性,以及密码子12缬氨酸与早期死亡率的关联。
J Pathol. 1998 Jun;185(2):130-8. doi: 10.1002/(SICI)1096-9896(199806)185:2<130::AID-PATH85>3.0.CO;2-M.

引用本文的文献

1
The Impact of and the Genotypic Biomarker KRAS on Colorectal Cancer Pathogenesis.[因素名称]及基因生物标志物KRAS对结直肠癌发病机制的影响 。 注:原文中“the Impact of and”这里“of”后面似乎缺失内容。
Int J Mol Sci. 2025 Jul 20;26(14):6958. doi: 10.3390/ijms26146958.
2
Therapeutic advances of targeting receptor tyrosine kinases in cancer.靶向治疗癌症受体酪氨酸激酶的治疗进展。
Signal Transduct Target Ther. 2024 Aug 14;9(1):201. doi: 10.1038/s41392-024-01899-w.
3
The Abundance of KRAS and RAS Gene Mutations in Cancer.癌症中 KRAS 和 RAS 基因突变的丰度。
Methods Mol Biol. 2024;2797:13-22. doi: 10.1007/978-1-0716-3822-4_2.
4
A Challenging Correlation between Tumor Cellularity and Somatic Variant Allele Fraction in Lung and Colorectal Cancers-Specimens of Low Tumor Percentage Should Be Analyzed with Caution.肺癌和结直肠癌中肿瘤细胞密度与体细胞变异等位基因分数之间具有挑战性的相关性-低肿瘤百分比标本应谨慎分析。
Biomolecules. 2024 Jan 31;14(2):168. doi: 10.3390/biom14020168.
5
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?晚期结直肠癌二线治疗中 BRAF 或 KRAS p.G12C 突变的动态变化:是否存在早晚期效应?
Br J Cancer. 2024 Mar;130(5):777-787. doi: 10.1038/s41416-023-02563-w. Epub 2024 Jan 8.
6
Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma.评估不同 KRAS 亚型作为肺腺癌免疫检查点抑制剂疗效的潜在生物标志物。
Front Immunol. 2023 Oct 24;14:1297588. doi: 10.3389/fimmu.2023.1297588. eCollection 2023.
7
Different oncological features of colorectal cancer codon-specific mutations: Not codon 13 but codon 12 have prognostic value.结直肠癌密码子特异性突变的不同肿瘤学特征:具有预后价值的不是密码子 13,而是密码子 12。
World J Gastroenterol. 2023 Aug 28;29(32):4883-4899. doi: 10.3748/wjg.v29.i32.4883.
8
Genomic landscape and expression profile of consensus molecular subtype four of colorectal cancer.结直肠癌共识分子亚型四的基因组景观和表达谱。
Front Immunol. 2023 Jun 19;14:1160052. doi: 10.3389/fimmu.2023.1160052. eCollection 2023.
9
RAS-targeted cancer therapy: Advances in drugging specific mutations.RAS靶向癌症治疗:针对特定突变的药物研发进展
MedComm (2020). 2023 May 27;4(3):e285. doi: 10.1002/mco2.285. eCollection 2023 Jun.
10
Clinical significance of the mutation in anastomotic recurrence of colorectal cancer.突变在结直肠癌吻合口复发中的临床意义。
Oncol Lett. 2023 Mar 28;25(5):192. doi: 10.3892/ol.2023.13778. eCollection 2023 May.